Want to see AU:TRP full AI Analyst Report?
Top Page
Tissue Repair Ltd
(Sydney:TRP)
Select Model
Select Model
Rating:46Neutral
Price Target:
AU$0.09
▲(10.00% Upside)
Action:Reiterated
Date:07/24/26
The score is held back primarily by sustained losses and ongoing cash burn (negative EBIT/net income and negative free cash flow), despite strong recent revenue acceleration and a debt-free balance sheet. Technically, the stock remains in a clear downtrend with weak momentum, while valuation signals are limited due to a negative P/E and no dividend yield data.
Positive Factors
Revenue Acceleration
Sharp revenue acceleration demonstrates meaningful product/market traction and growing commercial adoption. Sustained top-line growth over multiple quarters can support scale efficiencies, reduce marginal funding needs, and improve the path to sustainable profitability over a 2–6 month horizon if execution continues.
Negative Factors
Persistent Cash Burn
Consistent negative operating and free cash flow indicates the business is consuming cash faster than it generates it. Over several quarters this creates runway risk and a high probability of needing external financing, which can dilute shareholders or shift strategic priorities away from long-term projects.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Acceleration
Sharp revenue acceleration demonstrates meaningful product/market traction and growing commercial adoption. Sustained top-line growth over multiple quarters can support scale efficiencies, reduce marginal funding needs, and improve the path to sustainable profitability over a 2–6 month horizon if execution continues.
Read all positive factors
Tissue Repair Ltd (TRP) vs. iShares MSCI Australia ETF (EWA)
Market Cap
AU$5.44M
Dividend YieldN/A
Average Volume (3M)93.72K
Price to Earnings (P/E)―
Beta (1Y)1.34
Revenue Growth82.28%
EPS Growth13.33%
CountryAU
Employees5
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.06
Shares Outstanding60,464,844
10 Day Avg. Volume171,402
30 Day Avg. Volume93,720
Financial Highlights & Ratios
PEG Ratio-1.06
Price to Book (P/B)0.80
Price to Sales (P/S)4.25
P/FCF Ratio-2.71
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Tissue Repair Ltd Business Overview & Revenue Model
Company Description
Tissue Repair Ltd (TRP.AX) is an Australian clinical-stage biopharmaceutical firm dedicated to pioneering advanced solutions for wound care. The company's primary focus lies in developing treatments for persistent chronic wounds and enhancing reco...
How the Company Makes Money
null...
Tissue Repair Ltd Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
55
Neutral
Cash Flow
28
Negative
| Breakdown | TTM | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 | Jun 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.28M | 2.63M | 152.24K | 3.08K | 171.92K | 152.64K |
| Gross Profit | 1.98M | 2.63M | 150.51K | 428.00 | 170.21K | 152.64K |
| EBITDA | -4.81M | -4.72M | -6.51M | -5.14M | -7.01M | -189.44K |
| Net Income | -3.85M | -4.24M | -4.14M | -4.17M | -6.84M | -915.23K |
Balance Sheet | ||||||
| Total Assets | 12.44M | 14.57M | 19.39M | 22.38M | 25.90M | 27.61M |
| Cash, Cash Equivalents and Short-Term Investments | 8.29M | 12.32M | 16.44M | 21.40M | 25.46M | 27.11M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 7.50M |
| Total Liabilities | 607.50K | 662.53K | 1.35M | 497.35K | 559.64K | 536.00K |
| Stockholders Equity | 11.83M | 13.91M | 18.04M | 21.88M | 25.34M | 27.07M |
Cash Flow | ||||||
| Free Cash Flow | -5.70M | -4.12M | -4.95M | -4.26M | -3.97M | -852.89K |
| Operating Cash Flow | -5.27M | -3.70M | -4.95M | -4.26M | -3.97M | -852.89K |
| Investing Cash Flow | -432.20K | -421.67K | -3.35K | -2.24K | -3.92K | 5.00K |
| Financing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 21.36M | 7.46M |
Tissue Repair Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | AU$2.66B | -19.57 | -16.10% | ― | 1069.25% | 18.67% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | AU$51.95M | -0.41 | -131.13% | ― | 2086.71% | -116.20% | |
46 Neutral | AU$5.44M | -1.42 | -29.91% | ― | 82.28% | 13.33% | |
46 Neutral | AU$11.75M | -2.42 | -161.62% | ― | 76.94% | 42.95% | |
41 Neutral | AU$198.80M | -14.34 | -44.80% | ― | 49.03% | -232.68% | |
40 Underperform | AU$5.90M | -1.72 | -211.88% | ― | 250.37% | 71.29% |
* Healthcare Sector Average
AU:TRP
Tissue Repair Ltd
0.08
-0.26
-75.59%
AU:ACR
Acrux
0.01
>-0.01
-31.25%
AU:MSB
Mesoblast Limited
2.23
-0.08
-3.46%
AU:OCC
Orthocell Ltd
0.73
-0.49
-40.16%
AU:CMB
Regeneus Ltd.
0.41
-0.01
-2.38%
AU:BOT
Botanix Pharmaceuticals Limited
0.02
-0.13
-84.67%
Tissue Repair Ltd Corporate Events
Tissue Repair Advances Wound Care Trials and Strengthens Cash Position Ahead of Key Regulatory Milestones
Jul 31, 2026
Tissue Repair Ltd reported strong operational progress in the June 2026 quarter, highlighting its U.S. Phase III chronic wound trial, where about 100 patients have been randomised and recruitment continues. The company remains on track to file a U...
Tissue Repair Moves to Delist from ASX Amid Low Liquidity and High Costs
Jul 22, 2026
Tissue Repair Limited has applied to be removed from the Australian Securities Exchange official list under ASX Listing Rule 17.11, following in-principle advice from the exchange that it is likely to agree subject to shareholder approval and a mi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.